These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34253136)

  • 1. Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options.
    Le Calvez B; Moreau P; Touzeau C
    Expert Opin Investig Drugs; 2021 Sep; 30(9):965-973. PubMed ID: 34253136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma.
    Jelinek T; Paiva B; Hajek R
    Front Immunol; 2018; 9():2431. PubMed ID: 30505301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma.
    Hradska K; Kascak M; Hajek R; Jelinek T
    Expert Rev Hematol; 2020 Apr; 13(4):375-392. PubMed ID: 32116068
    [No Abstract]   [Full Text] [Related]  

  • 4. A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myeloma.
    Oriol A
    Expert Rev Hematol; 2020 May; 13(5):435-445. PubMed ID: 32182438
    [No Abstract]   [Full Text] [Related]  

  • 5. Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials.
    Hall PE; Schmid P
    Expert Opin Emerg Drugs; 2021 Jun; 26(2):131-147. PubMed ID: 33870839
    [No Abstract]   [Full Text] [Related]  

  • 6. The challenges of checkpoint inhibition in the treatment of multiple myeloma.
    Paul B; Kang S; Zheng Z; Kang Y
    Cell Immunol; 2018 Dec; 334():87-98. PubMed ID: 30342750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Bai J; Liang P; Li Q; Feng R; Liu J
    Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited treatment options in refractory multiple myeloma: promising therapeutic developments.
    Oriol A; Abril L; Ibarra G; Senin A
    Expert Rev Anticancer Ther; 2020 Jan; 20(1):31-44. PubMed ID: 31865804
    [No Abstract]   [Full Text] [Related]  

  • 9. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma.
    Chan LL; Chan SL
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):39-52. PubMed ID: 33724135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors in multiple myeloma: A review of the literature.
    Caserta S; Innao V; Musolino C; Allegra A
    Pathol Res Pract; 2020 Oct; 216(10):153114. PubMed ID: 32853951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
    Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
    Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now?
    Htut M
    Curr Hematol Malig Rep; 2019 Feb; 14(1):1-10. PubMed ID: 30666505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.
    Green SE; McCusker MG; Mehra R
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):501-514. PubMed ID: 33196319
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma.
    D'Agostino M; Gazzera G; Cetani G; Bringhen S; Boccadoro M; Gay F
    Curr Med Chem; 2019; 26(32):5968-5981. PubMed ID: 29756564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of daratumumab for the treatment of multiple myeloma.
    Cejalvo MJ; Ribas P; de la Rubia J
    Expert Opin Drug Saf; 2017 Jun; 16(6):753-760. PubMed ID: 28490215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.
    Curti BD; Koguchi Y; Leidner RS; Rolig AS; Sturgill ER; Sun Z; Wu Y; Rajamanickam V; Bernard B; Hilgart-Martiszus I; Fountain CB; Morris G; Iwamoto N; Shimada T; Chang S; Traber PG; Zomer E; Horton JR; Shlevin H; Redmond WL
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel investigational drugs active as single agents in multiple myeloma.
    D'Agostino M; Salvini M; Palumbo A; Larocca A; Gay F
    Expert Opin Investig Drugs; 2017 Jun; 26(6):699-711. PubMed ID: 28448171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?
    Sponaas AM; Waage A; Vandsemb EN; Misund K; Børset M; Sundan A; Slørdahl TS; Standal T
    Front Immunol; 2021; 12():636375. PubMed ID: 33679794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.